Literature DB >> 33641080

Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Harshad Devarbhavi1, Guruprasad Aithal2, Sombat Treeprasertsuk3, Hajime Takikawa4, Yimin Mao5, Saggere M Shasthry6, Saeed Hamid7, Soek Siam Tan8, Cyriac Abby Philips9, Jacob George10, Wasim Jafri7, Shiv K Sarin11.   

Abstract

Idiosyncratic drug-induced liver injury mimics acute and chronic liver disease. It is under recognized and underrecognised because of the lack of pathognomonic diagnostic serological markers. Its consequences may vary from being asymptomatic to self-limiting illness to severe liver injury leading to acute liver failure. Its incidence is likely to be more common in Asia than other parts of the world, mainly because of hepatotoxicity resulting from the treatment of tuberculosis disease and the ubiquitous use of traditional and complimentary medicines in Asian countries. This APASL consensus guidelines on DILI is a concise account of the various aspects including current evidence-based information on DILI with special emphasis on DILI due to antituberculosis agents and traditional and complementary medicine use in Asia.

Entities:  

Keywords:  APASL; Antituberculosis drugs; Consensus; DILI; Drug-induced liver injury; Guidelines; Hepatotoxicity; Medications; Monitoring; Risk factors; Traditional and complimentary medicine; Treatment; Tuberculosis

Year:  2021        PMID: 33641080     DOI: 10.1007/s12072-021-10144-3

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  154 in total

1.  Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.

Authors:  Thomas J Moore; Michael R Cohen; Curt D Furberg
Journal:  Arch Intern Med       Date:  2007-09-10

2.  A prospective nationwide study of drug-induced liver injury in Korea.

Authors:  Ki Tae Suk; Dong Joon Kim; Chang Hoon Kim; Seung Ha Park; Jai Hoon Yoon; Yeon Soo Kim; Gwang Ho Baik; Jin Bong Kim; Young Oh Kweon; Byung Ik Kim; Seok Hyun Kim; In Hee Kim; Ju Hyun Kim; Soon Woo Nam; Yong Han Paik; Jeong Ill Suh; Joo Hyun Sohn; Byung Min Ahn; Soon Ho Um; Heon Ju Lee; Mong Cho; Myoung Kuk Jang; Sung Kyu Choi; Seong Gyu Hwang; Ho Taik Sung; Jong Young Choi; Kwang Hyub Han
Journal:  Am J Gastroenterol       Date:  2012-06-26       Impact factor: 10.864

Review 3.  An official ATS statement: hepatotoxicity of antituberculosis therapy.

Authors:  Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling
Journal:  Am J Respir Crit Care Med       Date:  2006-10-15       Impact factor: 21.405

4.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

Authors:  Einar S Björnsson; Ottar M Bergmann; Helgi K Björnsson; Runar B Kvaran; Sigurdur Olafsson
Journal:  Gastroenterology       Date:  2013-02-16       Impact factor: 22.682

5.  Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network.

Authors:  Helgi K Björnsson; Einar S Björnsson; Bharathi Avula; Ikhlas A Khan; Jon G Jonasson; Marwan Ghabril; Paul H Hayashi; Victor Navarro
Journal:  Liver Int       Date:  2020-02-11       Impact factor: 5.828

Review 6.  Case definition and phenotype standardization in drug-induced liver injury.

Authors:  G P Aithal; P B Watkins; R J Andrade; D Larrey; M Molokhia; H Takikawa; C M Hunt; R A Wilke; M Avigan; N Kaplowitz; E Bjornsson; A K Daly
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

7.  Incidence and Etiology of Drug-Induced Liver Injury in Mainland China.

Authors:  Tao Shen; Yingxia Liu; Jia Shang; Qing Xie; Jun Li; Ming Yan; Jianming Xu; Junqi Niu; Jiajun Liu; Paul B Watkins; Guruprasad P Aithal; Raúl J Andrade; Xiaoguang Dou; Lvfeng Yao; Fangfang Lv; Qi Wang; Yongguo Li; Xinmin Zhou; Yuexin Zhang; Peilan Zong; Bin Wan; Zhengsheng Zou; Dongliang Yang; Yuqiang Nie; Dongliang Li; Yuya Wang; Xi'an Han; Hui Zhuang; Yimin Mao; Chengwei Chen
Journal:  Gastroenterology       Date:  2019-02-08       Impact factor: 22.682

8.  Incidence of drug-induced hepatic injuries: a French population-based study.

Authors:  Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

9.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

Authors:  G Danan; C Benichou
Journal:  J Clin Epidemiol       Date:  1993-11       Impact factor: 6.437

10.  Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

Authors:  M Isabel Lucena; Raúl J Andrade; Neil Kaplowitz; Miren García-Cortes; M Carmen Fernández; Manuel Romero-Gomez; Miguel Bruguera; Hacibe Hallal; Mercedes Robles-Diaz; Jose F Rodriguez-González; Jose Maria Navarro; Javier Salmeron; Pedro Martinez-Odriozola; Ramón Pérez-Alvarez; Yolanda Borraz; Ramón Hidalgo
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

View more
  15 in total

Review 1.  Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.

Authors:  Alessio Aghemo; Olga P Alekseeva; Francesco Angelico; Igor G Bakulin; Natalia V Bakulina; Dmitry Bordin; Alexey O Bueverov; Oxana M Drapkina; Anton Gillessen; Elvira M Kagarmanova; Natalia V Korochanskaya; U A Kucheryavii; Leonid B Lazebnik; Maria A Livzan; Igor V Maev; Anatolii I Martynov; Marina F Osipenko; Evgenii I Sas; Antonina Starodubova; Yurii P Uspensky; Elena V Vinnitskaya; Emilia P Yakovenko; Alexey A Yakovlev
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

2.  Heart-leaved Moonseed- Innocuous or Baneful.

Authors:  Deepakkumar Gupta; Amey Sonawane
Journal:  J Clin Exp Hepatol       Date:  2021-08-26

Review 3.  The therapeutic potential of exosomes derived from different cell sources in liver diseases.

Authors:  Yun Pan; Wei-Feng Tan; Mu-Qing Yang; Ji-Yu Li; David A Geller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-02-02       Impact factor: 4.052

4.  Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.

Authors:  Carlos K H Wong; Ivan C H Au; Wing Yiu Cheng; Kenneth K C Man; Kristy T K Lau; Lung Yi Mak; Sing Leung Lui; Matthew S H Chung; Xi Xiong; Eric H Y Lau; Benjamin J Cowling
Journal:  Aliment Pharmacol Ther       Date:  2022-03-22       Impact factor: 9.524

Review 5.  Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.

Authors:  Joseph William Clinton; Sara Kiparizoska; Soorya Aggarwal; Stephanie Woo; William Davis; James H Lewis
Journal:  Drug Saf       Date:  2021-09-17       Impact factor: 5.606

Review 6.  Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review.

Authors:  Mirjana Stanić Benić; Lana Nežić; Vesna Vujić-Aleksić; Liliana Mititelu-Tartau
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

7.  Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury.

Authors:  Shuang Zhao; Haoshuang Fu; Tianhui Zhou; Minghao Cai; Yan Huang; Qinyi Gan; Chenxi Zhang; Cong Qian; Jiexiao Wang; Zhenglan Zhang; Xiaolin Wang; Xiaogang Xiang; Qing Xie
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

8.  Targeted Metabolomics Analysis of Bile Acids in Patients with Idiosyncratic Drug-Induced Liver Injury.

Authors:  Zhongyang Xie; Lingjian Zhang; Ermei Chen; Juan Lu; Lanlan Xiao; Qiuhong Liu; Danhua Zhu; Fen Zhang; Xiaowei Xu; Lanjuan Li
Journal:  Metabolites       Date:  2021-12-08

Review 9.  Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review.

Authors:  Meng Li; Qiong Luo; Yanyan Tao; Xin Sun; Chenghai Liu
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

10.  The Correlated Risk Factors for Severe Liver Damage Among HIV-Positive Inpatients With Abnormal Liver Tests.

Authors:  Sheng Liu; Ying Zhou; Yu Wang; Cheng Bo Li; Wen Wang; Xu Lu; Pei Liu; Qing Hai Hu; Ying Wen
Journal:  Front Med (Lausanne)       Date:  2022-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.